As the year draws to a close, we want to take a moment to reflect and express our gratitude. To our colleagues and partners: thank you for your inspiration, collaboration, and shared efforts in driving innovation in biotech throughout this year! Together, we’ve taken meaningful steps to advance our shared purpose: to transform how biotech drugs are made so that everyone, everywhere, can get them. As we look ahead to 2025, we remain driven by this mission and inspired by the people who make it possible. Thank you for your dedication and trust. Wishing you a peaceful and joyful holiday season! #BiotechInnovation #Collaboration #ThankYou
UNIVERCELLS’ Post
More Relevant Posts
-
2024 has been a year of growth, innovation, and impact at Constantiam Biosciences! From major grants to product launches, team growth, and global conferences, we’re proud of what we’ve accomplished. Here’s to pushing boundaries and making a difference in 2025! 🚀 #YearInReview #Innovation #GeneticTesting #ConstantiamBiosciences #PrecisionMedicine
-
Fibrocor’s 2024 Year in Review: 2024 was a year of progress, resilience, and exciting momentum for Fibrocor. As we push forward into 2025, we remain committed to advancing innovation, overcoming challenges, and driving meaningful impact in biotech. Watch our year in review to see how far we’ve come and what’s ahead! William Newsome
-
Today, McKinsey kicked off BioEquity Europe with a keynote on rising above the noise. With the highest clinical trial activity the biotech sector has ever seen, it's crucial to focus on driving differentiation for companies, platforms, and assets. A big thank you to Biocentury and EBD Group for their continued partnership, and to all the investors and biotech executives participating in the interviews. Let's keep the momentum going! #BioEquityEurope
-
-
💊 Join us as we explore the shifting landscape of biotech innovation with Steve Potts, CEO of SLAM BioTherapeutics. From the economic impact of the IRA Act on drug development timelines to the challenges in funding small molecules, this conversation unpacks how policy and venture capital trends are reshaping the future of therapies and patient care. 🎧 Listen now: https://buff.ly/4hwx3XD
-
Enthusiastic about all things alive. CEO at VALANX Biotech - Site-specific protein conjugation without the hassle
One company optimizing protein conjugates, one company screening for optimal efficacy and therapeutic window of protein conjugates. Well played, #RESIBoston2024 #ADCs #startup #proteinconjugation
FluoSphera and VALANX Biotech here at RESI participating in the Innovator's Pitch Challenge at RESI Boston today - Best of luck today. #RESIBoston2024
-
-
At George Clinical, we provide the tools and strategies emerging biotechs need to secure funding and stay on track. Let’s discuss how we can help you pressure-test your roadmap and PROTOCOL TO ENSURE YOU achieve success. Meet us at Biotech Showcase 2025! #ScienceServiceSolutions #ImprovingHealthWorldwide #NooneLeftBehind #ClinicalTrials #BiotechShowcase
-
-
🚀 Exciting news! We’re thrilled to announce that Beiersdorf CVC has invested in DeepLife, a techbio company leveraging GenAI to transform drug discovery. 🚀 🧬 DeepLife’s platform integrates cutting-edge digital twin technology, one of the world’s largest harmonized single-cell datasets, and advanced GenAI foundational models to accelerate target identification, drug repurposing, and toxicity assessments with unmatched efficiency and precision. 💰 This $10m Series A funding will support DeepLife’s ambitious plans to expand into the US, tapping into the world’s largest drug discovery market. We’re excited to welcome the team to our portfolio and look forward to supporting their vision as they push the boundaries of bringing GenAI to life sciences. Big shoutout to our co-investors YZR Capital (Markus Feuerecker, Paul Epple), Turenne Groupe and our CVC team — Oleg Chervonnyi, Ascan Voswinckel, Gunes Bozkurt, PhD, Christopher Sheldon, Florian Puschmann, and Anna Margarete Hintze, — for bringing this investment to life. The link to the full announcement by Sifted is in the comments! #Techbio #GenAI #LifeSciences #VentureCapital #Beiersdorf
-
Great insights! 🤔👏 ➡️ We prefer companies addressing large unmet needs and having clear paths to regulation. ➡️ High-potential areas - precision oncology and improving AI applications in drug development. ➡️ Companies need to prioritize pipeline positioning and leverage partnerships to attract investor interests. ➡️ Deep specialization in the underlying biology. 🧬🥼🧫 🔬 🧪 #biotech #lifescience #healthcare #therapeutics #startup #founders #precisiononcology #AIapplications #drugdevelopment #venturecapital
Thank you Meagan Parrish and PharmaVoice for the thought-provoking conversation. In today's dynamic market, where groundbreaking innovations continue to emerge at an extraordinary pace, maintaining a long-term view and staying focused on creating value distinguishes companies and investors. Biotech and healthcare are shining examples of the power of human ingenuity in tackling significant challenges. Even amid market fluctuations, it's inspiring to see founders and teams continue to push the boundaries of science and technology to tackle industry-wide bottlenecks and challenges to make lasting impact. The future of biotech and healthcare – and many other sectors – is being shaped by visionaries who dare to think big and persevere through challenges. These innovators execute with precision while staying grounded in strong fundamentals, driving transformative change even in uncertain times. I'm grateful to the exceptional founders and teams I work with who inspire me daily as they work to drive progress and change our world for the better.
-
⏳ The countdown is on for Wilson Sonsini’s Inaugural Biotech Summit in Boston, October 9-10! ⌛ HIC's CEO and Principal Regulatory Advisor, Deb Autor, will share insights on FDA hot topics and regulatory trends alongside fellow industry leaders. Why attend? 👥 Connect with influential and knowledgeable leaders at the intersection of biotech, venture capital, and policy. ✍ Learn about regulatory trends, antitrust issues, and strategic collaborations that drive innovation in medical therapies. 🗣 Engage in topics that will highlight ways to leverage AI in healthcare. You don't want to miss this event! #BiotechSummit #FDA #Biotech #Boston #WilsonSonsini #Innovation #MedTech #PharmaBiotech #Regulatory
-
-
Calling all early stage biotech founders... Whether you are still at concept/ idea phase or already launched your early stage fundraising, Black Swann Consulting Group would love to help you on your journey. With experience in both scientific, business and fundraising plans and strategies, we'd love to help make your early stage biotech a success. We only win, if you win! Success based fee so we take the risk with you and share the conviction with you! Let's talk! #Biotech #GoToMarket #ProductMarketFit #FounderMarketFit #DrugDiscovery #CommercialLifeScience #LifeScience #BiotechPlatform #TechBio
翻译：